(Q38150875)

29 August 2017

title

Systemic therapies in hepatocellular carcinoma: present and future (English)

1 reference

29 August 2017

main subject

hepatocellular carcinoma

1 reference

Gaetano Bertino

1

1 reference

29 August 2017

Isidoro Di Carlo

2

1 reference

29 August 2017

Annalisa Ardiri

3

1 reference

29 August 2017

Giuseppe Stefano Calvagno

4

1 reference

29 August 2017

Shirin Demma

5

1 reference

29 August 2017

Giulia Malaguarnera

6

1 reference

29 August 2017

Nicoletta Bertino

7

1 reference

29 August 2017

Mariano Malaguarnera

8

1 reference

29 August 2017

Adriana Toro

9

1 reference

29 August 2017

Michele Malaguarnera

10

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

9

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1533-1548

1 reference

Risk stratification for hepatitis B virus related hepatocellular carcinoma

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Epidemiology of hepatocellular carcinoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Hepatocellualar carcinoma serum markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Elevated serum levels of Chromogranin A in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Novel advancements in the management of hepatocellular carcinoma in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Transarterial chemoembolization of hepatocellular carcinoma--agents and drugs: an overview. Part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Systemic therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Evolution of systemic therapy of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Increased Lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Hepatitis B virus X gene and hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Regulatory T cells in HBV and HCV liver diseases: implication of regulatory T lymphocytes in the control of immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Targeting the HGF/c-MET pathway in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sorafenib for treatment of hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Novel therapeutics in hepatocellular carcinoma: how can we make progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Tivantinib in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Brivanib: a review of development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Adoptive immunotherapy for postoperative hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Multifaceted kinetics of immuno-evasion from tumor dormancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Combination of radiofrequency ablation and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Current practice of chronic hepatitis B treatment in Southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Cellular immune suppressor mechanisms in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

HCC and angiogenesis: possible targets and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Targeted agents and systemic therapy in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

Serum markers of intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.13.171

21 January 2018

Identifiers

DOI

10.2217/FON.13.171

1 reference

29 August 2017

1 reference